targetedoncdotcom today 10/25/13....good message here...
"A third study is looking at the VEGF receptor TKI cabozantinib, which is approved for progressive metastatic medullary thyroid cancer. “Cabozantinib is somewhat different from the other agents in the field in that it blocks the VEGF receptors and the receptor MET,” George said. “This is a biology we think is very important in kidney cancer, particularly in patients who have progressed on the VEGF inhibitors. The protein that binds and activates the MET receptor, called hepatocyte growth factor (HGF), is made in the liver, but also in tumors. It’s responsible for cell motility. It may also help blood vessels grow in tumors. Inhibiting both VEGFR and MET together results in treatment effects following progression on VEGF receptor TKIs. We saw this drug working in an earlier study in a large number of patients who had failed other VEGF receptor TKIs. So it’s now being studied compared to everolimus in patients who have progressed on a prior VEGFR TKI.”